American Regenerative Clinic
- Ozone Therapy
- IV Therapy
- Laser Therapy (LLLT)
- Hyperbaric Oxygen Therapy (HBOT)
- Oxygen Therapy
Beverly Hills, MI
Beverly Hills supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Cedars-Sinai and UCLA Health, and stem cell practice in the area spans the Golden Triangle, Wilshire Corridor, and Beverly Hills medical offices. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. SB 1004 (2017) requires written disclosure when stem cell therapy is not FDA-approved. The Medical Board of California regulates physician practice under Business and Professions Code 651. Proposition 71 (2004) established the California Institute for Regenerative Medicine (CIRM). The FDA secured a 2022 permanent injunction against the California Stem Cell Treatment Center over non-compliant adipose SVF products. The 20 Beverly Hills clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and California Medical Board licensure checks.
Regulatory context
Michigan cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Michigan for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. The state has both academic IND research programs and direct-to-patient regenerative clinics.
The FDA has issued warning letters to Michigan clinics offering stem cell and exosome therapies. The Michigan Department of Licensing and Regulatory Affairs can discipline physicians through the Boards of Medicine and Osteopathic Medicine for unprofessional conduct including misleading regenerative medicine advertising. The Michigan Attorney General has pursued enforcement against providers making unsupported clinical claims, though the Smith v Globe Life decision has somewhat narrowed Consumer Protection Act application against licensed professionals. Federal warning letters apply nationally and Michigan clinics that source unapproved cellular products face the same regulatory exposure.
Explore related care